Please assess the completion status of the following clinical trial:

Trial Title: Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Age 18 years to 60 years~* Average to low daily physical activity~* Ability to ambulate for 75 meters without assistive devices~* Diagnosis of BMD confirmed by at least one the following:~  * Dystrophin immunofluorescence and/or immunoblot showing partial dystrophin deficiency, and clinical picture consistent with typical BMD, or~ * Gene deletions test positive (missing one or more exons) of the dystrophin gene, where reading frame can be predicted as 'in-frame', and clinical picture consistent with typical BMD, or~ * Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, or other mutation resulting in a stop codon mutation) that can be definitely associated with BMD, with a typical clinical picture of BMD, or~ * Positive family history of BMD confirmed by one of the criteria listed above in a sibling or maternal uncle, and clinical picture typical of BMD.~* Nutritional, herbal and antioxidant supplements taken with the intent of maintaining or improving skeletal muscle strength or functional mobility have been discontinued at least 2 weeks prior to screening (daily multivitamin use is acceptable).~* Hematology profile within normal range~* Baseline laboratory safety chemistry profile within normal range~* No plan to change exercise regimen during study participation~Exclusion Criteria:~* Currently enrolled in another treatment clinical trial.~* History of significant concomitant illness or significant impairment of renal or hepatic function.~* Use of regular daily aspirin or other medication with antiplatelet effects within 3 weeks of first dose of study medication.~* Regular participation in vigorous exercise.~* Symptomatic heart failure with cardiac ejection fraction \<25%

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treatment with Epicatechin (Type: EXPERIMENTAL): Purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).